Many issues may negatively influence the first year response to GH treatment, including GH injection problems, an inappropriate GH starting dose, a hidden growth limiting disease, or additional hormonal deficiencies appearing during GH therapy (e.g. central hypothyroidism) (7). This evidence concerns the gene GH1 and Central hypothyroidism.